These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36174408)

  • 21. Myasthenia gravis crisis.
    Bershad EM; Feen ES; Suarez JI
    South Med J; 2008 Jan; 101(1):63-9. PubMed ID: 18176295
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myasthenia gravis treated in the neurology intensive care unit: a 14-year single-centre experience.
    Zdraljevic M; Peric S; Jeremic M; Lavrnic D; Basta I; Hajdukovic L; Jovanovic DR; Berisavac I
    Neurol Sci; 2022 Dec; 43(12):6909-6918. PubMed ID: 36076000
    [TBL] [Abstract][Full Text] [Related]  

  • 23. COVID-19 pandemic year in a sample of Polish myasthenia gravis patients: an observational study.
    Rzepiński Ł; Zawadka-Kunikowska M
    Neurol Neurochir Pol; 2022; 56(1):61-67. PubMed ID: 34346049
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How the application of human immunoglobulin in the treatment of myasthenia crisis changed the outcome of the disease.
    Suljic E; Kavazovic A; Loncarevic N
    Med Arh; 2010; 64(1):7-10. PubMed ID: 20422815
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of the COVID-19 pandemic on patients with myasthenia gravis: A survey of the Myasthenia Gravis Foundation of America MG patient registry.
    De León AM; Aban I; McPherson T; Granit V; Benatar M; Cutter G; Lee I
    Muscle Nerve; 2023 Jan; 67(1):25-32. PubMed ID: 36324261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial.
    Zinman L; Ng E; Bril V
    Neurology; 2007 Mar; 68(11):837-41. PubMed ID: 17353471
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Maintenance IVIg therapy in myasthenia gravis does not affect disease activity.
    Hellmann MA; Mosberg-Galili R; Lotan I; Steiner I
    J Neurol Sci; 2014 Mar; 338(1-2):39-42. PubMed ID: 24267740
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Baseline Decrement in Patients with Mild Myasthenia Gravis Predicts Immunomodulation Treatment.
    Abraham A; Lovblom LE; Bril V
    Can J Neurol Sci; 2019 Nov; 46(6):762-766. PubMed ID: 31322098
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subcutaneous Immunoglobulin Therapy in the Chronic Management of Myasthenia Gravis: A Retrospective Cohort Study.
    Bourque PR; Pringle CE; Cameron W; Cowan J; Chardon JW
    PLoS One; 2016; 11(8):e0159993. PubMed ID: 27490101
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myasthenia gravis--treatment of acute severe exacerbations in the intensive care unit results in a favourable long-term prognosis.
    Spillane J; Hirsch NP; Kullmann DM; Taylor C; Howard RS
    Eur J Neurol; 2014; 21(1):171-3. PubMed ID: 23398500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative analysis of therapeutic options used for myasthenia gravis.
    Mandawat A; Kaminski HJ; Cutter G; Katirji B; Alshekhlee A
    Ann Neurol; 2010 Dec; 68(6):797-805. PubMed ID: 21061395
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravenous immunoglobulin as treatment for myasthenia gravis: current evidence and outcomes.
    Alabdali M; Barnett C; Katzberg H; Breiner A; Bril V
    Expert Rev Clin Immunol; 2014 Dec; 10(12):1659-65. PubMed ID: 25331319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidemiology, symptomatology and treatment of patients with myasthenia gravis in an Australian hospital.
    Li V; Jasinarachchi M; Butler E
    Intern Med J; 2019 Dec; 49(12):1537-1540. PubMed ID: 31808263
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in quality of life scores with intravenous immunoglobulin or plasmapheresis in patients with myasthenia gravis.
    Barnett C; Wilson G; Barth D; Katzberg HD; Bril V
    J Neurol Neurosurg Psychiatry; 2013 Jan; 84(1):94-7. PubMed ID: 23154126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunoadsorption apheresis versus intravenous immunoglobulin therapy for exacerbation of myasthenia gravis.
    Yasuda M; Uzawa A; Ozawa Y; Kojima Y; Onishi Y; Akamine H; Kuwabara S
    Scand J Immunol; 2022 Feb; 95(2):e13122. PubMed ID: 34796975
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma exchange versus intravenous immunoglobulin for myasthenia gravis crisis: an acute hospital cost comparison study.
    Heatwole C; Johnson N; Holloway R; Noyes K
    J Clin Neuromuscul Dis; 2011 Dec; 13(2):85-94. PubMed ID: 22361692
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Normal human immunoglobulin suppresses experimental myasthenia gravis in SCID mice.
    Vassilev T; Yamamoto M; Aissaoui A; Bonnin E; Berrih-Aknin S; Kazatchkine MD; Kaveri SV
    Eur J Immunol; 1999 Aug; 29(8):2436-42. PubMed ID: 10458757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myasthenia Gravis and COVID-19: Clinical Characteristics and Outcomes.
    Camelo-Filho AE; Silva AMS; Estephan EP; Zambon AA; Mendonça RH; Souza PVS; Pinto WBVR; Oliveira ASB; Dangoni-Filho I; Pouza AFP; Valerio BCO; Zanoteli E
    Front Neurol; 2020; 11():1053. PubMed ID: 33013676
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of COVID-19 infection among myasthenia gravis patients- a Cerner Real-World Data
    Digala LP; Prasanna S; Rao P; Qureshi AI; Govindarajan R
    BMC Neurol; 2022 Jan; 22(1):38. PubMed ID: 35086486
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multidisciplinary treatment for prepubertal juvenile myasthenia gravis with crisis.
    Hirata Y; Inoue M; Nabatame S; Okumura M; Ozono K
    Pediatr Int; 2016 Aug; 58(8):772-4. PubMed ID: 27324449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.